Skip Navigation LinksHome > March 2013 - Volume 56 - Issue 1 > Development and Impact of Human Papillomavirus Vaccines
Clinical Obstetrics & Gynecology:
doi: 10.1097/GRF.0b013e31827af770
Screening Tests for Cervical Cancer

Development and Impact of Human Papillomavirus Vaccines

DARUS, CHRISTOPHER J. MD; MUELLER, JENNIFER J. MD

Collapse Box

Abstract

Cervical cancer is a global health crisis that disproportionately affects developing nations and underserved populations. Two vaccines targeting HPV-16 and 18, which account for 70% of invasive cervical carcinomas, are licensed in the United States and numerous countries worldwide. Both vaccine formulations have shown excellent efficacy with minimal toxicity. Numerous questions remain, including cost-effectiveness, vaccination of males, societal acceptance of HPV vaccination, and cervical dysplasia screening in the HPV-immunized population. Access to vaccination for underserved populations both in developed and resource-poor nations remains an issue. Multivalent vaccines that encompass additional oncogenic HPV strains are under development.

© 2013 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.